Peer-reviewed by 2 reviewers with median rating of 16.5/20. Review process was triple-blinded.
Round 1 (12/20)
Round 2 (16.5/20)
Conceptual advance and Impact3.5
I would comment my concerns one by one. First of all, title contains abbreviation which should be indicated as official naming. Concerning data, the authors only showed the results on 24hrs treatment. But it should be shown the time-course of the reaction. Otherwise, we cannot argue their clinical relevance.
For general readers, abbreviation of "LXR" should be changed into "Liver X receptor.
In the manuscript, the label for Figure 1 is written as "a". This is confusing and needs to be fixed. The authors only showed the results on 24 hrs treatment. In terms of this kind reaction, we need time-course of the reaction.
Moreover, the authors had better showing the effects of LXR antagonist on sphingolipids metabolism.
Conceptual advance and Impact9
This manuscript presents intriguing and novel data to suggest that LXR activation not only modulates cholesterol metabolism, but also the synthesis of sphingolipids. This finding, if validated in other tissues offers novel insight into a number of diseases in which sphingolipids play a role. I could find nothing wrong with this novel and interesting report.